2017 Fiscal Year Final Research Report
Identification of peptides which can be applied to cancer vaccine therapy for patients with prostate cancer
| Project/Area Number |
15K10612
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Urology
|
|---|
| Research Institution | Kindai University |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2015-04-01 – 2018-03-31
|
| Keywords | ペプチドワクチン |
|---|
| Outline of Final Research Achievements |
3~5 prostate cancer-associated antigens (PTH-rP,EGFR,EZH2) -derived peptides that were prepared based on the binding motif to the HLA-A3 supertype alleles (HLA-A11, -A31, and -A33) were functionally screened for their potential to induce peptide-specific cytotoxic T lymphocytes (CTLs) from peripheral blood mononuclear cells (PBMCs) of 12 HLA-A3 supertype allele+ prostate cancer patients. As a result, EZH2733-741 peptide was found to efficiently induce peptide-specific CTLs. To test cytotoxicity of CTLs by a standard 6-h 51Cr-release assay, CD8+ T cells were purified from EZH2733-741 peptide-stimulated PBMCs. The EZH2733-741 peptide-stimulated and purified CD8+ T cells from PBMCs of HLA-A3 supertype allele+ prostate cancer patients showed higher cytotoxicity against HLA-A3 supertype allele-expressing LNCaP prostate cancer cells than against parental LNCaP cells.
|
| Free Research Field |
泌尿器科学
|
